title: The safety of etretinate as long-term therapy for psoriasis: results of the etretinate follow-up study.
abstract: BACKGROUND
  Etretinate is an aromatic retinoid given orally to treat severe psoriasis, a chronic disease that often requires long-term therapy.
  
  
  OBJECTIVE
  We assessed the safety of long-term therapy with etretinate for psoriasis.
  
  
  METHODS
  This 5-year prospective study of a cohort of 956 patients with psoriasis treated with etretinate assessed the frequency of adverse events in relation to total use and in relation to the frequency of these events in control populations.
  
  
  RESULTS
  Our data do not provide evidence for an increased risk of cardiovascular disease, cancer, diabetes, or inflammatory bowel disease in association with long-term etretinate use. Although some patients reported that joint problems improved with the use of etretinate, a greater number associated the use of etretinate with joint problems.
  
  
  CONCLUSIONS
  With proper patient selection and monitoring, long-term etretinate therapy (up to 4 years) does not appear to be accompanied by a substantial increased risk of major adverse effects.
authors.affiliation: Department of Dermatology, Beth Israel Hospital, Boston, MA 02215, USA.
authors.forename: R S
authors.initials: RS
authors.lastname: Stern
authors.forename: E
authors.initials: E
authors.lastname: Fitzgerald
authors.forename: C N
authors.initials: CN
authors.lastname: Ellis
authors.forename: N
authors.initials: N
authors.lastname: Lowe
authors.forename: M T
authors.initials: MT
authors.lastname: Goldfarb
authors.forename: R D
authors.initials: RD
authors.lastname: Baughman
mesh_terms: D000328:Adult; D005050:Etretinate / Q000009:adverse effects* / Q000627:therapeutic use; D005128:Eye Diseases / Q000139:chemically induced / Q000453:epidemiology; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D015994:Incidence; D007592:Joint Diseases / Q000139:chemically induced / Q000453:epidemiology; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000139:chemically induced / Q000453:epidemiology; D009369:Neoplasms / Q000139:chemically induced / Q000453:epidemiology; D011701:PUVA Therapy; D011247:Pregnancy; D011248:Pregnancy Complications / Q000188:drug therapy / Q000453:epidemiology; D011446:Prospective Studies; D011565:Psoriasis / Q000188:drug therapy* / Q000401:mortality; D013997:Time Factors
chemical_list: D005050:Etretinate